Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Investors Should Take a Bigger Position When Teledoc Posts a Strong Quarter

By Chris Lau, InvestorPlace Contributor May 9, 2022

First-quarter revenue miss reset Teladoc’s prospects for shareholders, pressuring the company to accelerate its multi-product launch.

Watch This Next Major Event for SoFi Technologies Stock

By Chris Lau, InvestorPlace Contributor May 5, 2022

Sofi’s quarterly earnings report is a turning point for shareholders, as the company’s CEO must earn back investor confidence.

Is Microsoft Stock Worth Buying After Surging Higher?

By Chris Lau, InvestorPlace Contributor May 3, 2022

Microsoft is a buy, not only because its cloud unit reported exceptional growth but also on rejuvenated PC sales growth ahead.

What Just Happened to Shopify Stock?

By Chris Lau, InvestorPlace Contributor May 2, 2022

Investors eagerly await the quarterly report for SHOP stock, a potential turning point to shift negative sentiment to positive.

7 Safe Stocks to Buy in May 2022